Your browser doesn't support javascript.
loading
Rituximab-treated patients with lymphoma develop strong CD8 T-cell responses following COVID-19 vaccination.
Riise, Jon; Meyer, Saskia; Blaas, Isaac; Chopra, Adity; Tran, Trung T; Delic-Sarac, Marina; Hestdalen, Malu Lian; Brodin, Ellen; Rustad, Even Holth; Dai, Ke-Zheng; Vaage, John Torgils; Nissen-Meyer, Lise Sofie Haug; Sund, Fredrik; Wader, Karin F; Bjornevik, Anne T; Meyer, Peter A; Nygaard, Gro O; König, Marton; Smeland, Sigbjørn; Lund-Johansen, Fridtjof; Olweus, Johanna; Kolstad, Arne.
Afiliação
  • Riise J; Department of Oncology, Oslo University Hospital, Oslo, Norway.
  • Meyer S; Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.
  • Blaas I; Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
  • Chopra A; Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.
  • Tran TT; Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
  • Delic-Sarac M; Department of Immunology, Oslo University Hospital, Oslo, Norway.
  • Hestdalen ML; Department of Immunology, Oslo University Hospital, Oslo, Norway.
  • Brodin E; Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.
  • Rustad EH; Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
  • Dai KZ; Department of Hematology, Division of Medicine, Akershus University Hospital, Lørenskog, Norway.
  • Vaage JT; Hematological Research Group, Division of Medicine, Akershus University Hospital, Lørenskog, Norway.
  • Nissen-Meyer LSH; Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.
  • Sund F; Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
  • Wader KF; Hematological Research Group, Division of Medicine, Akershus University Hospital, Lørenskog, Norway.
  • Bjornevik AT; Department of Immunology, Oslo University Hospital, Oslo, Norway.
  • Meyer PA; Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
  • Nygaard GO; Department of Immunology, Oslo University Hospital, Oslo, Norway.
  • König M; Department of Immunology, Oslo University Hospital, Oslo, Norway.
  • Smeland S; Department of Oncology, University Hospital of North Norway, Tromsø, Norway.
  • Lund-Johansen F; Department of Oncology, St Olav University Hospital, Trondheim, Norway.
  • Olweus J; Department of Oncology, Haukeland University Hospital, Bergen, Norway.
  • Kolstad A; Department of Oncology and Hematology, Stavanger University Hospital, Stavanger, Norway.
Br J Haematol ; 197(6): 697-708, 2022 06.
Article em En | MEDLINE | ID: mdl-35254660
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Linfócitos T CD8-Positivos / Rituximab / Vacinas contra COVID-19 / COVID-19 / Linfoma Limite: Humans Idioma: En Revista: Br J Haematol Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Noruega
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Linfócitos T CD8-Positivos / Rituximab / Vacinas contra COVID-19 / COVID-19 / Linfoma Limite: Humans Idioma: En Revista: Br J Haematol Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Noruega